[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605305":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":31,"collaborators":11,"id":33,"slug":11,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":11,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":11,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":54,"whyStopped":11,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":11},{"fullName":5,"class":6},"Onconic Therapeutics Inc.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: JP-1366 A mg + Placebo","EXPERIMENTAL",null,[13],"Drug: JP-1366 + placebo",{"label":15,"type":10,"description":11,"interventionNames":16},"Group 2: JP-1366 B mg + Placebo",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Placebo + Placebo","PLACEBO_COMPARATOR",[21],"Drug: Placebo + Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","JP-1366 + placebo","taking JP-1366 + placebo",[9,15],{"type":24,"name":18,"description":29,"armGroupLabels":30,"otherNames":11},"taking placebo + placebo",[18],{"type":32,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605305",false,"NCT07160790","Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease","Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux(NERD) Disease: Double-blind, Randomized","Inclusion Criteria:\n\n* Subjects who have experienced both heartburn and acid regurgitation\n* Subjects in whom no mucosal breaks were observed on upper GI endoscopy at Visit 1 by LA Classification\n* Subjects who fully understand this clinical trial and voluntarily signed the informed consent form\n\nExclusion Criteria:\n\n* Subjects who have significant gastrointestinal diseases or procedures affecting the esophagus, stomach, or duodenum\n* Subjects who have a history of recent substance abuse, malignancy, systemic autoimmune or immune deficiency diseases, refractory response to PPI\u002FP-CAB, hypersensitivity to study drugs, genetic metabolic disorders, or significant psychiatric conditions.\n* Subjects who showed clinically significant abnormalities in laboratory tests\n* Positive result in the H. pylori test\n* Pregnant or breast-feeding women\n* Subjects who require hospitalization are scheduled to undergo surgery during the study period, or have undergone major surgery requiring general anesthesia\n* Other people deemed unsuitable for participation in this study according to the medical opinion of the investigator","ALL","19 Years","75 Years",{"count":43,"type":44},321,"ESTIMATED","INTERVENTIONAL",[47],"PHASE3","This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD",[50],"Non-erosive Gastroesophageal Reflux Disease",[52,53],"Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease","NOT_YET_RECRUITING","2025-08-29",{"date":57,"type":58},"2025-09-08","ACTUAL",{"date":60,"type":44},"2025-09-02",{"date":62,"type":44},"2026-06-30",{"name":5,"class":6}]